Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain

Shunsuke Nakae, Takema Kato, Kazuhiro Murayama, Hikaru Sasaki, Masato Abe, Masanobu Kumon, Tadashi Kumai, Kei Yamashiro, Joji Inamasu, Mitsuhiro Hasegawa, Hiroki Kurahashi, Yuichi Hirose

Research output: Contribution to journalArticle

Abstract

Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.

Original languageEnglish
Pages (from-to)84729-84742
Number of pages14
JournalOncotarget
Volume8
Issue number49
DOIs
Publication statusPublished - 17-10-2017

Fingerprint

Glioma
Recurrence
Mutation
Astrocytoma
Neoplasms
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Nakae, Shunsuke ; Kato, Takema ; Murayama, Kazuhiro ; Sasaki, Hikaru ; Abe, Masato ; Kumon, Masanobu ; Kumai, Tadashi ; Yamashiro, Kei ; Inamasu, Joji ; Hasegawa, Mitsuhiro ; Kurahashi, Hiroki ; Hirose, Yuichi. / Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain. In: Oncotarget. 2017 ; Vol. 8, No. 49. pp. 84729-84742.
@article{5404fe32298049ebb3a95906ebb0d137,
title = "Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain",
abstract = "Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan{\circledR} arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.",
author = "Shunsuke Nakae and Takema Kato and Kazuhiro Murayama and Hikaru Sasaki and Masato Abe and Masanobu Kumon and Tadashi Kumai and Kei Yamashiro and Joji Inamasu and Mitsuhiro Hasegawa and Hiroki Kurahashi and Yuichi Hirose",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.20951",
language = "English",
volume = "8",
pages = "84729--84742",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain. / Nakae, Shunsuke; Kato, Takema; Murayama, Kazuhiro; Sasaki, Hikaru; Abe, Masato; Kumon, Masanobu; Kumai, Tadashi; Yamashiro, Kei; Inamasu, Joji; Hasegawa, Mitsuhiro; Kurahashi, Hiroki; Hirose, Yuichi.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 84729-84742.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain

AU - Nakae, Shunsuke

AU - Kato, Takema

AU - Murayama, Kazuhiro

AU - Sasaki, Hikaru

AU - Abe, Masato

AU - Kumon, Masanobu

AU - Kumai, Tadashi

AU - Yamashiro, Kei

AU - Inamasu, Joji

AU - Hasegawa, Mitsuhiro

AU - Kurahashi, Hiroki

AU - Hirose, Yuichi

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.

AB - Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.

UR - http://www.scopus.com/inward/record.url?scp=85031498436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031498436&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20951

DO - 10.18632/oncotarget.20951

M3 - Article

VL - 8

SP - 84729

EP - 84742

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -